Cannabidiol as a Potential Treatment for Anxiety Disorders: A Systematic Review
Abstract
A comprehensive meta-analysis of 49 studies found CBD demonstrated significant anxiolytic effects across multiple anxiety disorder subtypes, with a favorable safety profile compared to conventional pharmacotherapy. Effect sizes were moderate to large across GAD, SAD, and PTSD populations.
Study Summary
This systematic review synthesized evidence from 49 preclinical and clinical studies examining CBD's anxiolytic properties. The authors searched PubMed, EMBASE, and PsycINFO through December 2023. Included studies covered generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder, obsessive-compulsive disorder (OCD), and PTSD. CBD's anxiolytic mechanism is primarily attributed to 5-HT1A receptor agonism in the dorsal raphe nucleus and hippocampus, with additional contributions from CB1 receptor modulation and TRPV1 desensitization. Acute CBD administration (300–600mg) consistently reduced anxiety in human laboratory paradigms. Chronic dosing data were more limited. The review identified a biphasic dose-response relationship — moderate doses (150–300mg) appeared optimal, with higher doses showing diminishing returns. Compared to SSRIs and benzodiazepines, CBD showed a more favorable acute tolerability profile, though long-term comparative data are lacking.
Key Findings
- 1CBD demonstrated significant anxiolytic effects across GAD, SAD, and PTSD in 49 pooled studies
- 2Optimal acute dose range identified as 150–600mg; biphasic response observed at higher doses
- 35-HT1A receptor agonism identified as primary anxiolytic mechanism
- 4Favorable safety profile vs. conventional pharmacotherapy in short-term studies
- 5Chronic dosing evidence remains limited — most studies used single acute doses
Clinical Implications
- CBD may be a viable adjunct or alternative for anxiety disorders, particularly in patients intolerant of SSRIs
- Dose titration is important — the 150–300mg range appears most consistently effective
- Drug interactions with CYP3A4 substrates should be considered in polypharmacy patients
- Long-term RCT data are needed before CBD can be recommended as first-line anxiety treatment
Study Limitations
- High heterogeneity in study designs, doses, and outcome measures
- Most clinical studies used acute single-dose paradigms — limited chronic data
- Publication bias likely inflates apparent effect sizes
- Most human studies used healthy volunteers rather than clinical populations